Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and earnings for the second quarter of 2023.
- Second-quarter revenue came in at $1.61 billion, which is up 1% year-over-year
- Earnings per share increased to $0.95 in the June quarter from $0.92 last year
- Adjusted earnings were $1.31 per share in Q2, compared to $1.25 per share in the second quarter of 2022
- The company reported second-quarter adjusted EBITDA of $530 million, which is up 4% annually
- The management expects full-year 2023 revenue to be in the range of $6.25 billion to $6.45 billion
- Adjusted EBITDA margin for 2023 is currently expected to be between 31.5% and 33.0%
Most Popular
Infographic: How Lennar (LEN) performed in Q4 2025
Lennar Corporation (NYSE: LEN) reported total revenues of $9.4 billion for the fourth quarter of 2025, compared to $9.9 billion reported in the same period a year ago. Net earnings
Paychex expected to report higher revenue and earnings for Q2 FY26
Paychex, Inc. (NASDAQ: PAYX), a leading provider of human capital management solutions, is undergoing an AI-driven transformation that enhances both its internal operations and client-facing services. Entering fiscal 2026, the
Signet Jewelers (SIG): A look at the progress made on Grow Brand Love
Shares of Signet Jewelers Limited (NYSE: SIG) fell over 3% on Tuesday. The stock has gained 3% year-to-date. The jewelry retailer delivered strong results for the third quarter of 2026,
